middle.news
Syntara Charts FDA-Backed Phase 2 Path for Amsulostat in Myelofibrosis
9:58am on Monday 11th of August, 2025 AEST
•
Healthcare
Read Story
Syntara Charts FDA-Backed Phase 2 Path for Amsulostat in Myelofibrosis
9:58am on Monday 11th of August, 2025 AEST
Key Points
FDA advises Phase 2 controlled trial for amsulostat in myelofibrosis
Focus on symptom improvement and spleen volume reduction endpoints
Syntara to refine clinical plan and pursue partnerships
Robust pipeline with multiple candidates targeting blood cancers and fibrosis
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE